Gaviscon 500 + 267 mg / 10 ml oral suspension - contrasts stomach heartburn 24 mint flavour bags

Product Description

Symptomatic treatment of occasional heartburn.

Indications

Gaviscon 500mg/10ml + 267mg/10ml mint-flavored oral suspension, neutralises excess stomach acid and forms a protective barrier that floats on the stomach contents, preventing their reflux.

Mint flavor.

Composition

Active ingredients

10 ml contain: Active ingredients: sodium alginate 500 mg; sodium bicarbonate 267 mg. Excipients with known effects: methyl parahydroxybenzoate 40 mg; propyl parahydroxybenzoate 6 mg.

Excipients

Calcium carbonate, carbomers, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium saccharin, mint flavoring, sodium hydroxide, purified water.

Directions for use and dosage

Adults and adolescents (12-18 years): 10-20 ml (second-fourth notch of the measuring cup or 2-4 measuring spoons or 1-2 single-dose sachets) after meals and at bedtime.
Method of administration: For oral administration.
Shake the suspension before use.

Warnings

Do not use for prolonged treatments.
In adolescents (12-18 years), use only if clearly needed and under strict medical supervision. Renal insufficiency: In case of renal insufficiency, the medicine must be used with caution since the exogenous saline supplement provided by antacids can cause potentially serious electrolyte imbalances. Each single-dose sachet of 500 mg + 267 mg oral powder contains 123 mg (5.3 mmol) of sodium.
This should be taken into account in cases where a particularly low-salt diet is recommended, for example in some cases of congestive heart failure and renal impairment.
Each single-dose sachet of 500 mg + 267 mg oral powder contains 160 mg (1.6 mmol) of calcium carbonate.
Caution should be exercised when treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones.
The tablets and oral powder contain aspartame, a source of phenylalanine: it should therefore not be taken by patients with phenylketonuria.
The suspension contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions.
Generally, delayed reactions (contact dermatitis) occur, rarely immediate reactions with urticaria and bronchospasm.
Duration of treatment: If symptoms do not improve after seven days, the clinical picture should be re-evaluated.

Contraindications

Hypersensitivity to the active substances or to any of the excipients.

Interactions

It is advisable to leave an interval of at least two hours between taking Gaviscon and that of other drugs, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates and estramustine.

Undesirable effects

The following are the undesirable effects of Gaviscon, organised according to the MedDRA system organ classification.
They are divided by frequency (very common (≥ 1/10), common (≥ 1/100 to ≤ 1/10), uncommon (≥ 1/1,000 to ≤ 1/100), rare (≥ 1/10,000 to 1/1,000), very rare (≤ 1/10,000)).

Overdose

Experience with overdose is very limited.
The only possible consequence of overdose is abdominal distension: in this case, resort to symptomatic treatment and adopt general supportive measures.

Pregnancy and breastfeeding

Use only if clearly needed and under strict medical supervision.

Storage

Mint-flavored oral suspension in sachets: do not store above 25°C. Store in the original packaging. Do not refrigerate. Mint-flavored chewable tablets: do not store above 30°C. Store in the original packaging.

Format

24 sachets